Intensive Care Medicine

, Volume 30, Issue 12, pp 2188–2196

Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects

  • Yahya Shehabi
  • Urban Ruettimann
  • Harriet Adamson
  • Richard Innes
  • Mathieu Ickeringill
Original

Abstract

Objective

To assess the potential of dexmedetomidine for targeted sedation in complex Intensive Care (ICU) patients for >24 h.

Design

Prospective, open label, clinical trial.

Setting

Tertiary general ICU.

Patients

Twenty critically ill patients, mean APACHE II 23(±9).

Interventions

A continuous infusion of dexmedetomidine, median infusion time 71.5 (35–168) h, starting at 0.4μg·kg·h without a loading dose and adjusted (0.2–0.7μg·kg·h) to a target Ramsay Sedation Score (RSS) of 2–4. Rescue midazolam and/or morphine/fentanyl were given as clinically indicated.

Measurements and results

Haemodynamic parameters and RSSs were collected until 24 h after cessation. An RSS 2–5 was achieved in 1,147 (83%) of observations with a reduction in RSS of 6 from 13% in the first 6 h to 3% between 18 h and 24 h. Sixteen patients needed minimal or no additional midazolam, median 4 mg/day (0.5–10) and ten required minimal or no additional analgesia, median 2 mg/day (0.5–4.5), 55μg/day (14–63) of morphine/fentanyl.

Results

A 16% reduction in mean systolic blood pressure (SBP) and 21% reduction in heart rate (HR) occurred over the first 4 h followed by minimal (± 10%) changes throughout the infusion. A rise in SBP was observed in two patients. After abrupt cessation, SBP and HR monitored for 24 h rose by 7% and 11%, respectively.

Conclusions

Dexmedetomidine was an effective sedative and analgesic sparing drug in critically ill patients when used without a loading dose for longer than 24 h with predictable falls in blood pressure and HR. There was no evidence of cardiovascular rebound 24 h after abrupt cessation of infusion.

Keywords

Dexmedetomidine Sedatives Intensive care unit Analgesics 

References

  1. 1.
    Kress JP, Pohlman AS, O’Connor MF, Hall JB (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. New Engl J Med 342:1471–1477CrossRefPubMedGoogle Scholar
  2. 2.
    Bhana N, Goa KL, McClellan KJ (2000) Dexmedetomidine. Drugs 59:263–268PubMedGoogle Scholar
  3. 3.
    Talke P, Chen R, Thomas B, Aggarwall A, Gottlieb A, Thorborg P, Heard S, Cheung A, Son SL, Kallio A (2000) The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg 90:834–839CrossRefPubMedGoogle Scholar
  4. 4.
    Triltsch AE, Welte M, von Homeyer P, Grosse J, Genahr A, Moshirzadeh M, Sidiropoulos A, Konertz W, Kox WJ, Spies CD (2002) Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo–controlled phase II study. Crit Care Med 30:1007–10014CrossRefPubMedGoogle Scholar
  5. 5.
    Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, Vedio A, Singer M, Feneck R, Treacher D, Willatts SM, Grounds RM (1999) Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 54:1136–1142CrossRefPubMedGoogle Scholar
  6. 6.
    Venn RM, Hell J, Grounds RM (2000) Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care (London) 4:302–308Google Scholar
  7. 7.
    Venn RM, Grounds RM (2001) Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth 87:684–690CrossRefPubMedGoogle Scholar
  8. 8.
    Venn M, Newman J, Grounds M (2003) A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 29:201–207PubMedGoogle Scholar
  9. 9.
    Herr DL, Sum-Ping ST, England M (2003) ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesthes 17:576–584CrossRefGoogle Scholar
  10. 10.
    Venn RM, Karol MD, Grounds RM (2002) Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth 88:669–775CrossRefPubMedGoogle Scholar
  11. 11.
    Belleville JP, Ward DS, Bloor BC, Maze M (1992) Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 77:1125–1133PubMedGoogle Scholar
  12. 12.
    Cummings DM, Vlasses PH (1982) Antihypertensive drug withdrawal syndrome. Drug Intel Clin Pharm 16:817–8122Google Scholar
  13. 13.
    Geyskes GG, Boer P, Dorhout Mees EJ (1979) Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clinical Pharmac 7:55–62Google Scholar
  14. 14.
    Lowenthal DT, Saris S, Paran E, Cristal N, Sharif K, Bies C, Fagan T (1986) Efficacy of clonidine as transdermal therapeutic system: the international clinical trial experience. Am Heart J 112:893–900CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Yahya Shehabi
    • 1
  • Urban Ruettimann
    • 1
  • Harriet Adamson
    • 1
  • Richard Innes
    • 1
  • Mathieu Ickeringill
    • 1
  1. 1.Prince of Wales HospitalBarker StreetRandwick 2031Australia

Personalised recommendations